Summary The effects of certain compounds on the in vitro growth rate and the sensitivity to doxorubicin of P388 murine leukaemia cell line and of a doxorubicin-resistant subline (P388/ADR) were studied.
Treatment of cancer patients with combinations of cytotoxic drugs has been shown, in many instances, to be more effective than single drug regimens, in controlling the disease. In recent years a number of investigators have shown in experimental systems that certain compounds that are not used as anticancer agents but rather for the treatment of other medical problems, enhanced the activity of certain anticancer drugs. Such compounds include some coronary vasodilators, tranquillizers, antifungal frugs, local anaesthetics and even surface active compounds used as pharmaceutical aids (Mizuno & Ishida, 1982a, b, c; Tsuruo et al., 1982 Tsuruo et al., ,1983a Ganapathi & Grabowski, 1983; Inaba et al., 1981; Ozols et al., 1983; Medoff et al., 1975; Valeriote et al., 1979; Klein & Frayer, 1978; Carlsen et al., 1976; Chlebowski et al., 1982; Riehm & Biedler, 1972; Bown & Goldman, 1975; Seeber et al., 1982) .
Recently, such synergism has been demonstrated between doxorubicin and compounds known either to have calcium channel blocking activity, or inhibitory activity of calmodulin mediated effects (Tsuruo et al., 1982 (Tsuruo et al., ,1983a Ganapathi & Grabowski, 1983) . Although calcium levels were not measured in these studies, Tsuruo et al. (1982 Tsuruo et al. ( ,1983a , suggested that the cellular calcium environment plays an important role in the manifestation of this synergism by controlling the efflux of the drug from the cells.
We have recently reported that perhexiline maleate enhances the uptake and the cytotoxic activity of doxorubicin, in a doxorubicin-resistant subline of P388 leukaemia cells but not in the parent drug-sensitive cell line (Ramu et al., 1984b) . This activity of perhexiline was not inhibited by increasing the concentration of calcium in the medium or by adding a calcium ionophore. Nor could it be imitated by reducing the concentration of the calcium in the medium, chelating the medium's calcium with ethyleneglycol bis (f,-aminoethyl ether)-N,N'-tetraacetic acid (EGTA), or by blocking, with lanthanum ions, the uptake of calcium into the cells. Therefore, although perhexiline maleate was shown to act as a calcium channel antagonist in exitable tissues (Fleckenstein, 1977) , it was suggested that its ability to enhance the cytotoxicity of doxorubicin in our system was unrelated to calcium antagonism. In the present study we report on the restoration of doxorubicin responsiveness in the doxorubicin-resistant P388 cells by some other drugs, not related to perhexiline and provide evidence that their effects are also unrelated to a calcium antagonistic activity.
Materials and methods
Cell culture P388 murine leukaemia cells and a subline resistant to doxorubicin (P388/ADR), were propagated continuously in suspension culture as previously described (Ramu et al., 1984b Initial cell density was I05 cells ml-1 and after 4 days in culture it was 1-2 x 106cells ml -1. Cell growth rates were calculated from the culture densities measured once a day for 4 days. Determination of drug sensitivity The sensitivity of a cell line to a given drug or a drug combination was assessed as follows: cells were cultured in the presence of various drug concentrations for 4 days and the slope of the log cell density versus time plot was calculated by linear regression analysis. The growth rate at each drug concentration was expressed as the percentage of the control growth rate. Dose-effect curves were thus produced and were used to determine the concentration of drug effective in inhibiting the growth rate by 50% (ED50). The doxorubicin ED 5 for the drug-sensitive and the drug-resistant cell lines ranged from 2-6 x 10-8M and from 1-2 x 10 -6M respectively. No change in drug sensitivity of either cell line was observed during 4 years of continuous in vitro culture.
Measurements of sodium-dependent and membrane potential-dependent calcium uptake in synaptic plasma membrane vesicles Synaptic plasma membrane vesicles were isolated from brain tissue of 14 day old rats as described by Rahamimoff & Spanier (1979) . Plasma membrane vesicles were also prepared from 109 P388 cells and from its doxorubicin-resistant subline. Mitochondrial contamination of the vesicle preparations was determined by measuring the specific activity of glutamic acid dehydrogenase as described by Erdreich et al (1983) . This contamination was found to be < 10%.
Calcium transport studies were done on vesicles pre-equilibrated by incubation at 370C with a solution containing either 0.15 M Na phosphate buffer, pH 7.4, or 0.15MK phosphate buffer, pH 7.4. The loaded vesicles were concentrated by centrifugation at 27,000g for 20min and suspended into a small amount of the same solution. Ionic gradients were formed by diluting 3 pl of these vesicles (about 30 
Results
A number of compounds were tested for synergistic activity to doxorubicin in P388 and P388/ADR cell cultures. In these experiments cells of both lines were exposed to each one of the tested compounds at a number of concentrations, either in the absence or in the presence of a non-inhibitory concentration of doxorubicin (10-8M for p388 cells and Table I The effect concentrations well below those having an independent growth-inhibitory effect of their own.
In order to characterize further the enhancement of doxorubicin inhibition of growth by dipyridamole, we measured the effects of increasing concentrations of doxorubicin on the growth rate of both cell lines in the presence of a non-inhibitory concentration (10-5M) of dipyridamole (Figure 2 ).
In the presence of dipyridamole there was a marked increase in the sensitivity of P388/ADR cells to doxorubicin. The ED50 was reduced from 9.6 x 10-7M in the absence of dipyridamole to 6.3 x 10-8 M in its presence. On the other hand, the sensitivity of P388 cells to doxorubicin was only minimally affected (ED50 reduced from 5.Ox 10-8M to 2.7x 10-8M). The effects of other compounds, at sub-inhibitory concentrations on the sensitivity of the P388/ADR cell line to doxorubicin are shown in Table II . From the data presented in this table as well as from those presented in Table I (Lee & Tsien, 1983; Reuter, 1983) . Other studies have also shown that lanthanum and verapamil can block the potential-dependent and sodium-dependent movements of calcium across the membrane of isolated brain synaptosomes (Erdreich et al., 1983; Gill et al., 1981; Nachshen & Blaustein, 1979) . We therefore examined whether in addition to verapamil, the other compounds, screened in this study for synergism to doxorubicin, can also block the calcium uptake into isolated synaptosomes. The inhibition of the sodium-dependent and membrane potential-dependent calcium uptake, obtained by these compounds, is shown in Table III. An appreciable uptake of calcium could not be obtained in sodium phosphate or potassium phosphate loaded membrane vesicles prepared from either cell line. Discussion Dopyridamole was found in the present study to be highly potent in restoring the sensitivity of P388/ADR cells to doxorubicin (Figures 1 and 2) . In previous studies, some of the pharmacological activities of dipyridamole were related to its ability to block adenosine uptake (Liu & Feinberg, 1973; Born & Mills, 1969) . Inhibition of adenosine uptake was also recently reported for phenothiazines like thioridazine (Phillis & Wu, 1981) . However, papaverine and nitrobenzylthioinosine, which are also effective inhibitors of adenosine uptake (Born & Mills, 1969; Lauzon & Paterson, 1977) , do not have doxorubicin synergistic activity (Table I and Ramu et al., 1984a) . We therefore suggest that the doxorubicin synergistic effect of dipyridamole is not related to its ability to block adenosine transport.
The data presented in this study (Tables I and II (Triggle, 1982) . However, such an activity could not be demonstrated for dipyridamole (Table III and Mustafa & Nakagawa, 1983) . The inability of dipyridamole to block the sodium-dependent or the membrane potential-dependent calcium uptake in synaptic plasma membrane vesicles suggests that the synergism of these compounds with doxorubicin in the drug-resistant P388 cells is not related to calcium channel blocking activity. This suggestion is further supported by the findings that in plasma membrane vesicles, prepared from either P388 or P388/ADR cells, no sodium-dependent or membrane potential-dependent calcium uptake could be demonstrated. Furthermore, Toll (1982) has recently demonstrated that the calcium channel blocking activity in exitable membranes, by calcium (Table III) . However, the data presented in Tables I and II and in our previous study (Ramu et al., 1984b) suggest that this is not the case. This lack of correlation can also be demonstrated by comparing the doxorubicin synergistic activity of the so called calcium channel antagonists (Tsuruo et al., 1983b) , with their activity in blocking calcium channels (Fleckenstein, 1977; Lee & Tsien, 1983; Triggle, 1981 Triggle, , 1982 . As is shown in Tables I and II , nifedipine, unlike its structural analogue, nicardipine, has only a minimal doxorubicin synergistic activity. Similar results were obtained by others (Table III in Tsuruo et al., 1983a) . It is therefore suggested that the 2-(N-benzyl)-N-methylamino-ethyl moiety of the nicardipine is important for the doxorubicin synergistic activity of this drug. A similar structure can be found in meclizine, verapamil and more remotely in dipyridamol, perhexiline, chlorcyclizine, thioridazine, and MDL 6792.
In the present study, thioridazine was found to have a moderate synergism to doxorubicin in the P388/ADR cell line. Similar results were obtained with other phenothiazines (Tsuruo et al., 1982; Ganapathi & Grabowski, 1983; Inaba et al., 1981) . Recently, Kauffman & Conery (1983) have demonstrated that thioridazine and some other phenothiazines were effective inhibitors of the binding of [3H]-Nitrendipine to cardiac muscle cell membranes. However, as previously discussed, this characteristic does not seem related to the restoration of sensitivity to doxorubicin in drugresistant cells. There were also suggestions that the phenothiazines exert some of their pharmacological effects by blocking the calmodulin mediated activities (Weiss et al., 1980) . Subsequently it was suggested that the inhibition of the action of calmodulin is related to the synergism of these compounds with doxorubicin (Tsuruo et al., 1982) . In fact the ability to bind calmodulin and/or block its activities was also shown for some other doxorubicin synergistic compounds like verapamil, prenylamine, dilthiazem, nicardipine, nimodipine, dibucaine, propranolol and phentolamine (Johnson, 1983a,b; Epstein et al., 1982; Tsuruo et al., 1982; Volpi et al., 1981; Earl et al., 1982) . However, as in the case of calcium channel blockade, there is no correlation between the potencies of these drugs in inhibiting calmodulin-mediated effects and their activity in restoring the sensitivity of drug-resistant cells to doxorubicin. These and other drugs which were shown to antagonize calmodulin-induced activities are of a wide range of chemical classes and have a wide spectrum of pharmacological activities (Vincenzi, 1982) . It was suggested that a feature common to all these agents is that they are amphipathic and cationic at physiological pH, and that their binding to calmodulin is not particularly specific (Vincenzi, 1981) . These amphipathic cationic compounds can share other activities that are not calmodulin dependent . More relevant, perhaps, is the recent observation that the calmodulin inhibitory activity of many compounds is related to their ability to stabilize the erythrocyte membrane (Bereza et al., 1982) . It is therefore suggested that the doxorubicin synergistic activity of these compounds is related to their interaction with the cell membrane rather than to calcium channel blockade or to inhibition of calmodulin mediated drug efflux. In our previous studies (Ramu et al., 1983; 1984c) , major differences were found in the characteristics of the lipid domains of the plasma membrane of P388/ADR cells compared to those of the parent P388 cell line. Therefore the preferential enhancement, by these compounds, of the doxorubicin cytotoxicity in P388/ADR cells, may further indicate that specific interaction with the cell membrane lipid domain, is related to the doxorubicin synergistic activity.
The present results indicate that certain drugs restore the effectiveness of doxorubicin against resistant cells in vitro. They imply that concomitant administration of these drugs in patients may result in enhanced chemotherapeutic activity of doxorubicin in refractory patients. The finding that the increase in doxorubicin potency was not observed in drug sensitive cells suggest that the synergism may be limited to the drug-resistant cells. However, prior to clinical trials, in vitro studies demonstrating no decrease in the therapeutic index of doxorubicin in the presence of these drugs are needed.
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